Westpac Banking Corp Purchases 9,231 Shares of Moderna, Inc. $MRNA

Westpac Banking Corp purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 9,231 shares of the company’s stock, valued at approximately $1,778,000.

A number of other institutional investors have also recently added to or reduced their stakes in MRNA. Ethic Inc. lifted its stake in Moderna by 23.6% in the third quarter. Ethic Inc. now owns 19,394 shares of the company’s stock valued at $3,735,000 after purchasing an additional 3,700 shares during the last quarter. Merck & Co. Inc. bought a new position in Moderna during the second quarter valued at $161,642,545. Bank of New York Mellon Corp purchased a new stake in Moderna in the second quarter worth $119,168,000. TD Waterhouse Canada Inc. increased its position in Moderna by 2,042.6% in the third quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock worth $13,722,000 after buying an additional 69,203 shares during the last quarter. Finally, Contravisory Investment Management Inc. increased its position in Moderna by 1,387.6% in the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock worth $1,696,000 after buying an additional 22,590 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Recent Moderna Headlines

Investors following MRNA have been watching these headlines:

  • Positive Sentiment: Moderna’s personalized melanoma vaccine, used with Merck’s Keytruda, reduced the risk of recurrence or death in a Phase 3 trial. The results support the potential of its oncology pipeline, although positive trial news has not prevented the recent pullback. Article: Moderna's Cancer Vaccine Worked
  • Positive Sentiment: A report says Morgan Stanley sees potential for substantial share-price appreciation, offering a more optimistic view amid recent volatility. Article: Morgan Stanley Forecasts Strong Price Appreciation
  • Negative Sentiment: President Stephen Hoge sold shares in transactions reported for November 16 and 17, and coverage noted the stock fell below its 50-day moving average. The sales were made under a pre-arranged Rule 10b5-1 plan, so they do not necessarily signal a change in his view of the company, but they may add to near-term selling pressure. Article: Moderna President Sells Shares

Insiders Place Their Bets

In other Moderna news, President Stephen Hoge sold 39,215 shares of the firm’s stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $211.61, for a total value of $8,298,286.15. Following the completion of the transaction, the president directly owned 1,311,095 shares of the company’s stock, valued at $277,440,812.95. This trade represents a 2.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Jamey Mock sold 34,836 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 275,626 shares of company stock worth $50,776,076 in the last three months. 10.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MRNA shares. CLSA raised Moderna to an “outperform” rating in a research report on Friday, August 28th. Deutsche Bank assumed coverage on Moderna in a report on Friday, August 28th. They issued a “hold” rating and a $125.00 price objective for the company. Bradesco Corretora raised Moderna to an “outperform” rating in a report on Friday, August 28th. Berenberg Bank boosted their price objective on Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research note on Friday, September 11th. Finally, Morgan Stanley upped their price objective on shares of Moderna from $95.00 to $200.00 and gave the company an “equal weight” rating in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $120.25.

View Our Latest Research Report on MRNA

Moderna Trading Down 2.6%

Shares of MRNA opened at $194.18 on Friday. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $280.80. The stock has a market cap of $78.57 billion, a PE ratio of -27.35 and a beta of 1.16. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The business’s 50-day moving average price is $207.87 and its 200-day moving average price is $100.37.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s revenue was up 29.2% compared to the same quarter last year. During the same period last year, the business earned ($0.51) earnings per share. On average, equities analysts forecast that Moderna, Inc. will post -5.40 EPS for the current fiscal year.

Moderna Company Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.